Clinical Trials

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02838420 2026-03-18

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

187 enrolled 14 charts

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

NCT03737994 2026-03-18

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

10 enrolled 17 charts

Lung Neoplasms

NCT03297606 2026-03-04

CAPTUR

720 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT04603807 2026-02-27

A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases

220 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03194893 2026-02-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

DermatologicGastrointestinal

200 enrolled

EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

NCT03947385 2026-01-27

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Phase 1/2 Recruiting

336 enrolled

Uveal Melanoma, Melanoma, Colorectal Neoplasms

NCT02201992 2025-12-19

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

166 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03052608 2025-11-25

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

296 enrolled 28 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT06140836 2025-11-21

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

190 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04439266 2025-11-19

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

LymphoidOther hematologic neoplasmPlasma cell

5 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06357975 2025-10-31

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

50 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT02767804 2025-10-14

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

290 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04439253 2025-09-18

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

LymphoidOther hematologic neoplasmPlasma cell

4 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT05160922 2025-09-03

Crizotinib Continuation Clinical Study

Phase 4 Active not recruiting

27 enrolled

LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT02075840 2025-07-25

ALEX

Phase 3 Completed

303 enrolled 31 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04030429 2025-07-16

Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer

Phase 2 Terminated

40 enrolled

Gynecologic

Endometrial Cancer Recurrent

NCT03375242 2025-06-25

Safety and Efficacy of Xalkori ROS1

Recruiting

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

423 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

44 enrolled 22 charts 1 FDA

770 enrolled

Rare Tumor

NCT01121588 2025-01-23

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Phase 1 Terminated

CNSLymphoid

Lymphoma, Neoplasms, Neuroblastoma

NCT02761057 2025-01-13

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

152 enrolled 19 charts

Genitourinary

Carcinoma, Renal Cell

NCT06563999 2024-12-10

NUMER

120 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03672643 2024-11-08

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Phase 4 Terminated

41 enrolled 9 charts

ALK or ROS1-positive NSCLC

NCT04322890 2024-10-22

PIKACHU

6,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06569420 2024-08-26

Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

275 enrolled

364 enrolled 89 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02679170 2024-08-09

Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

Completed

692 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT01712217 2024-08-02

A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Phase 1/2 Completed

220 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04084717 2024-07-16

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02473497 2024-06-26

Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients

No longer available

Tumor-Agnostic

Neoplasms

NCT04322578 2024-06-04

CONFIRM

120 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06254599 2024-02-12

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

255 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01606878 2024-01-05

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Phase 1 Completed

46 enrolled 24 charts

CNSLymphoid

Neuroblastoma, Lymphoma, Large-Cell, Anaplastic

NCT03646994 2023-12-27

Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

Unknown

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03647111 2023-12-27

Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer

Unknown

120 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01524926 2023-12-11

CREATE

LymphoidPlasma cellSarcoma

582 enrolled

Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Sarcoma, Clear Cell, Rhabdomyosarcoma, Alveolar, Sarcoma, Alveolar Soft Part

NCT02223819 2023-12-06

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

34 enrolled 9 charts

Dermatologic

Uveal Melanoma

NCT04632758 2023-11-24

Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 3 Unknown

292 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01744652 2023-06-07

Dasatinib and Crizotinib in Advanced Cancer

Phase 1 Completed

62 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Completed

549 enrolled 28 charts

ALK-positive NSCLC

NCT02419287 2023-03-06

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

12 enrolled

Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT05725200 2023-02-21

EVIDENT

40 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02612194 2022-11-03

LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer

Phase 2 Terminated

8 enrolled 16 charts

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT05467189 2022-07-20

Antineoplastic Drugs in Elderly Patients

Recruiting

500 enrolled

Tumor-Agnostic

Neoplasms

NCT02183870 2022-06-16

EUCROSS

34 enrolled